<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30427738</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Assessment of seroprevalence against poliovirus among Italian adolescents and adults.</ArticleTitle><Pagination><StartPage>677</StartPage><EndPage>682</EndPage><MedlinePgn>677-682</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2018.1547608</ELocationID><Abstract><AbstractText>In 2002, the WHO European Region was declared polio-free. Nonetheless global eradication has not yet been completed and the reintroduction from at risk areas is still possible. This seroprevalence study evaluated samples collected from each Italian region in the 12-50&#xa0;years old age range to assess protection against Poliovirus (PV) 1, 2 and 3 among subjects immunised with different vaccination schedules. 1073 samples (50.5% females) were examined. WHO standardized microneutralization assay was used. Seroprotection rates were 92.9%, 96.2% and 83.4%, for PV1, PV2 and PV3, respectively. Geometric Mean Titres (GMTs) were higher for PV2 (52.8) and PV1 (41.1) than for PV3 (21.0). Increasing the age, a decreasing trend in seropositivity was observed, in particular for PV3. The 2017-2019 Italian National Immunisation Plan emphasises, as primary objective, the maintenance of the polio-free status and strongly validates the 2&#xa0;+&#xa0;1 schedule in the first year of life with IPV vaccine associated with the administration of booster doses at 6&#xa0;years and during the adolescence. Surveillance system and high population immunity are crucial to ensure the maintenance of polio-free status.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lupi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5402-7888</Identifier><AffiliationInfo><Affiliation>a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanati</LastName><ForeName>Armando</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6094-3439</Identifier><AffiliationInfo><Affiliation>a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldovin</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7375-9187</Identifier><AffiliationInfo><Affiliation>b Department of Cardiac, Thoracic and Vascular Sciences, Hygiene and Public Health Unit , University of Padua , Padua , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roman</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5043-8858</Identifier><AffiliationInfo><Affiliation>a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldo</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>b Department of Cardiac, Thoracic and Vascular Sciences, Hygiene and Public Health Unit , University of Padua , Padua , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabutti</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>a Department of Medical Sciences , University of Ferrara , Ferrara , Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="N">Poliovirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">microneutralization assay</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">seropositivity</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30427738</ArticleId><ArticleId IdType="pmc">PMC6988879</ArticleId><ArticleId IdType="doi">10.1080/21645515.2018.1547608</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO) Polio vaccines: WHO position paper. Wkly Epidemiol Rec. 2016;91(12):145&#x2013;&#x2013;168..</Citation><ArticleIdList><ArticleId IdType="pubmed">27039410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC.. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci. 754;1995:289&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">7625665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia, PA: Elsevier-Saunders; 2017. p. 866&#x2013;917.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative  [Accessed
2018. 
February
2]. http://polioeradication.org/where-we-work/polio-endemic-countries/</Citation></Reference><Reference><Citation>Tafuri S, Prato R, Martinelli D, Calvario A, Bozzi A, Labianca M, Patti A, Lopalco PL, Germinario C. Serological survey on immunity status against polioviruses in children and adolescents living in a border region, Apulia (Southern Italy). BMC Infect Dis. 2008;8:.150. doi:10.1186/1471-2334-8-150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-8-150</ArticleId><ArticleId IdType="pmc">PMC2585574</ArticleId><ArticleId IdType="pubmed">18973678</ArticleId></ArticleIdList></Reference><Reference><Citation>Majori S, Baldo V, Poli A, Riolfatti M, Alborino F, Bonello C, Frau S, Baldovin T, Dal Zotto A, Romano G, et al. Immunity to poliovirus among children and the elderly in north-east Italy. J Prev Med Hyg. 2006;47(1):12&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17061405</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldo V, Baldovin T, Cocchio S, Lazzari R, Saracino E, Bertoncello C, Buja A, Trevisan A. Seroepidemiology of polioviruses among university students in northern Italy. Clin Vaccine Immunol. 2012;19(8):1292&#x2013;1295. doi:10.1128/CVI.00054-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00054-12</ArticleId><ArticleId IdType="pmc">PMC3416076</ArticleId><ArticleId IdType="pubmed">22739695</ArticleId></ArticleIdList></Reference><Reference><Citation>Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano. Accordo tra il Ministero della Salute, le Regioni e le Province Autonome di Trento e Bolzano sulle modifiche al calendario della vaccinazione antipoliomielitica; 2002. May 30 [Italian] 10.1044/1059-0889(2002/er01)</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/1059-0889(2002/er01)</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control 
Wild-type poliovirus 1 transmission in Israel &#x2013; what is the risk to the EU/EEA?
Stockholm, Sweden: ECDC; 2013.  [Accessed
2018
March
2]. http://ecdc.europa.eu/en/publications/Publications/polio-risk-assessment-transmission-in-Israel.pdf</Citation></Reference><Reference><Citation>Wallace GS, Curns AT, Weldon WC, Oberste MS. Seroprevalence of poliovirus antibodies in the United States population, 2009-2010. BMC Public Health. 2016;16:.721. doi:10.1186/s12889-016-3386-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-016-3386-1</ArticleId><ArticleId IdType="pmc">PMC4974751</ArticleId><ArticleId IdType="pubmed">27492318</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW. Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis. 2012;12:.24. doi:10.1186/1471-2334-12-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-12-24</ArticleId><ArticleId IdType="pmc">PMC3298481</ArticleId><ArticleId IdType="pubmed">22280025</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbiol Infect. 2005;11(1):68&#x2013;71. doi:10.1111/j.1469-0691.2004.00998.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2004.00998.x</ArticleId><ArticleId IdType="pubmed">15649308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill. 2007;12(6):E7&#x2013;E8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991403</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maas NA, Mollema L, Berbers GA, van Rooijen DM, van der Avoort HG, Conyn-Van Spaendonck MA, de Melker HE, van der Klis FR. Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series. Euro Surveill. 2014;19(7):20705. doi:10.2807/1560-7917.ES2014.19.7.20705.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2014.19.7.20705</ArticleId><ArticleId IdType="pubmed">24576472</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin N, Paterson BJ, Durrheim DN. Australia&#x2019;s polio risk. Commun Dis Intell Q Rep. 2014;38(2):E107&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25222205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace GS, Pahud BA, Weldon WC, Curns AT, Oberste MS, Harrison CJ. Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013. Hum Vaccin Immunother. 2017;13(4):776&#x2013;783. doi:10.1080/21645515.2016.1255386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1255386</ArticleId><ArticleId IdType="pmc">PMC5404638</ArticleId><ArticleId IdType="pubmed">28059613</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M, Montagnon B, Chalumeau H, Murray M, Wimmer E, Hovi T. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice. J Virol. 1990;64(2):559&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249144</ArticleId><ArticleId IdType="pubmed">1688625</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijsten D, Carrillo-Santisteve P, Miglietta A, Ruitenberg J, Lopalco PL. Is EU/EEA population protected from polio? Hum Vaccin Immunother. 2015;11(9):2123&#x2013;2131. doi:10.1080/21645515.2015.1016673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1016673</ArticleId><ArticleId IdType="pmc">PMC4635704</ArticleId><ArticleId IdType="pubmed">25898095</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronesi L, Affanni P, Verrotti Di Pianella C, Colucci ME, Tanzi ML. Immunity status against poliomyelitis in childbearing women in a province of northern Italy. A cross-sectional analysis. Ann Ig. 2013;25:427&#x2013;433. doi:10.7416/ai.2013.1944.</Citation><ArticleIdList><ArticleId IdType="doi">10.7416/ai.2013.1944</ArticleId><ArticleId IdType="pubmed">24048181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministero della Salute Piano Nazionale della Prevenzione Vaccinale 2017-2019. G.U. Serie Generale, n. 41 del 18 febbraio 2017 [Italian].</Citation></Reference><Reference><Citation>De Donno A, Kuhdari P, Guido M, Rota MC, Bella A, Brignole G, Lupi S, Idolo A, Stefanati A, Del Manso M, et al. Study Group on seroepidemiology. Has VZV epidemiology changed in Italy? Results of a seroprevalence study. Hum Vaccin Immunother. 2017;13(2):385&#x2013;390. doi:10.1080/21645515.2017.1264828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1264828</ArticleId><ArticleId IdType="pmc">PMC5328229</ArticleId><ArticleId IdType="pubmed">28027004</ArticleId></ArticleIdList></Reference><Reference><Citation>Foiadelli T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, Bino S, Amato C, Lozza A, Marseglia GL, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277. doi:10.1186/s12879-016-1587-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1587-y</ArticleId><ArticleId IdType="pmc">PMC4903009</ArticleId><ArticleId IdType="pubmed">27287521</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO) Polio laboratory manual. 4th ed Geneva, Switzerland: WHO/IVB/04.10; 2004.</Citation></Reference><Reference><Citation>World Health Organization (WHO) Manual for the virological investigation of polio. Geneva, Switzerland: WHO/EPI/GEN/97.01; 1997.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>